GlassScriptPhysician profile
Amanda J Kile
NPI 1255726295
$7,656.03
in general payments reported to CMS, 2019-2025
40 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $303 · 2021: $1,604 · 2022: $1,941 · 2023: $1,197 · 2024: $1,395 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,766 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,766.34 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,246.12 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $849.52 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $773.75 | 2020-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $490.41 | 2020-2025 | Korlym |
| Medtronic, INC. | $440.08 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $347.34 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $338.93 | 2022-2025 | |
| Radius Health, INC. | $323.22 | 2020-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $305.89 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $220.88 | 2021-2025 | Omnipod |
| Amgen INC. | $219.14 | 2021-2025 | Evenity, Tepezza, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.66 | 2020-2024 | Tradjenta, Synjardy, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $207.08 | 2021-2025 | |
| Abbvie INC. | $198.92 | 2021-2025 | |
| Mannkind Corporation | $188.56 | 2021-2025 | Afrezza |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $157.94 | 2021-2025 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $151.98 | 2022-2025 | Isturisa |
| Sanofi-Aventis U.S. LLC | $129.31 | 2020-2023 | |
| Lifescan, INC. | $111.48 | 2020-2021 | |
| Amarin Pharma, INC. | $107.30 | 2020-2021 | |
| Cequr Corporation | $100.89 | 2024-2025 | Cequr Simplicity |
| Ibsa Pharma INC. | $48.67 | 2021-2025 | Tirosint, Licart, Tirosint |
| Sequel Med Tech, LLC | $47.87 | 2025 | Twiist |
| Kyowa Kirin, INC. | $47.15 | 2023 | Crysvita |
| Ascendis Pharma Endocrinology INC | $41.97 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $37.13 | 2022-2024 | Strensiq |
| Tandem Diabetes Care, INC. | $33.65 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $32.74 | 2021 | |
| Glaxosmithkline, LLC. | $30.10 | 2022-2023 | Trelegy Ellipta |
| Medtronic Minimed, INC. | $28.86 | 2020 | |
| Halozyme INC | $28.30 | 2023 | |
| Becton, Dickinson and Company | $24.82 | 2021 | |
| Averitas Pharma INC. | $22.66 | 2023 | Qutenza |
| Eusa Pharma (US) LLC | $22.22 | 2022 | |
| Esperion Therapeutics, INC. | $17.71 | 2025 | Nexletol |
| Horizon Therapeutics Plc | $17.47 | 2021 | |
| Antares Pharma, INC. | $16.14 | 2025 | Xyosted |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.80 | 2022 | |
| Pfizer INC. | $13.77 | 2022 | |
| Neurocrine Biosciences, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Kile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.